Luca Issi
Stock Analyst at RBC Capital
(3.94)
# 622
Out of 5,124 analysts
216
Total ratings
49.63%
Success rate
10.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Outperform | $860 → $925 | $840.95 | +9.99% | 3 | Dec 17, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $82 → $95 | $79.11 | +20.09% | 11 | Dec 17, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $52 → $80 | $66.39 | +20.50% | 11 | Dec 11, 2025 | |
| WVE Wave Life Sciences | Upgrades: Outperform | $9 → $27 | $17.00 | +58.82% | 6 | Dec 9, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Sector Perform | $7 → $10 | $11.31 | -11.58% | 3 | Dec 8, 2025 | |
| MRNA Moderna | Maintains: Sector Perform | $28 → $25 | $29.49 | -15.23% | 18 | Nov 21, 2025 | |
| AGIO Agios Pharmaceuticals | Downgrades: Sector Perform | $57 → $28 | $27.22 | +2.87% | 1 | Nov 20, 2025 | |
| KRRO Korro Bio | Downgrades: Sector Perform | $85 → $8 | $8.01 | -0.12% | 8 | Nov 13, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Sector Perform | $42 → $50 | $52.44 | -4.65% | 15 | Nov 11, 2025 | |
| RGNX REGENXBIO | Maintains: Outperform | $17 → $19 | $14.41 | +31.85% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $14 → $9 | $8.99 | +0.11% | 7 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $30 | $19.56 | +53.37% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $45 | $23.93 | +88.05% | 7 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $61 → $72 | $72.13 | -0.18% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $435 → $500 | $397.65 | +25.74% | 28 | Sep 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $210 → $230 | $213.24 | +7.86% | 3 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.37 | +629.93% | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $18 | $25.12 | -28.34% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $9.93 | +101.41% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.42 | +376.19% | 6 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $12.14 | +40.09% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $7.95 | +63.52% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $7.50 | +366.67% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $26 | $27.72 | -6.20% | 7 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $59.43 | +17.79% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $38.38 | +48.51% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $2.05 | +95.12% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $23.00 | +234.78% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.59 | +780.50% | 5 | Aug 7, 2024 |
argenx SE
Dec 17, 2025
Maintains: Outperform
Price Target: $860 → $925
Current: $840.95
Upside: +9.99%
Ionis Pharmaceuticals
Dec 17, 2025
Maintains: Outperform
Price Target: $82 → $95
Current: $79.11
Upside: +20.09%
Arrowhead Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $52 → $80
Current: $66.39
Upside: +20.50%
Wave Life Sciences
Dec 9, 2025
Upgrades: Outperform
Price Target: $9 → $27
Current: $17.00
Upside: +58.82%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Sector Perform
Price Target: $7 → $10
Current: $11.31
Upside: -11.58%
Moderna
Nov 21, 2025
Maintains: Sector Perform
Price Target: $28 → $25
Current: $29.49
Upside: -15.23%
Agios Pharmaceuticals
Nov 20, 2025
Downgrades: Sector Perform
Price Target: $57 → $28
Current: $27.22
Upside: +2.87%
Korro Bio
Nov 13, 2025
Downgrades: Sector Perform
Price Target: $85 → $8
Current: $8.01
Upside: -0.12%
CRISPR Therapeutics AG
Nov 11, 2025
Maintains: Sector Perform
Price Target: $42 → $50
Current: $52.44
Upside: -4.65%
REGENXBIO
Nov 7, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $14.41
Upside: +31.85%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $14 → $9
Current: $8.99
Upside: +0.11%
Nov 6, 2025
Maintains: Outperform
Price Target: $23 → $30
Current: $19.56
Upside: +53.37%
Nov 4, 2025
Maintains: Outperform
Price Target: $65 → $45
Current: $23.93
Upside: +88.05%
Oct 28, 2025
Downgrades: Sector Perform
Price Target: $61 → $72
Current: $72.13
Upside: -0.18%
Sep 19, 2025
Maintains: Outperform
Price Target: $435 → $500
Current: $397.65
Upside: +25.74%
Aug 8, 2025
Maintains: Outperform
Price Target: $210 → $230
Current: $213.24
Upside: +7.86%
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $1.37
Upside: +629.93%
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $25.12
Upside: -28.34%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $9.93
Upside: +101.41%
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.42
Upside: +376.19%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $12.14
Upside: +40.09%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $7.95
Upside: +63.52%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $7.50
Upside: +366.67%
Feb 26, 2025
Maintains: Sector Perform
Price Target: $24 → $26
Current: $27.72
Upside: -6.20%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $59.43
Upside: +17.79%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $38.38
Upside: +48.51%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.05
Upside: +95.12%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $23.00
Upside: +234.78%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.59
Upside: +780.50%